Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?

European Journal of Cancer

Volumn 47, Issue 12, 2011, Pages 1759-1762

  Pignatti, Francesco ^a   Hemmings, Rob ^b   Jonsson, Bertil ^c  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER REGISTRY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG APPROVAL; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOLOGY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 80051543793     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.05.009     Document Type: Note

References (9)

1. Guideline on the evaluation of anticancer medicinal products in man; 2006. Available from: http://www.ema.europa.eu/ema/pages/includes/document/open- document.jsp?webContentId=WC500017748.
2. Guidance for industry, clinical trial endpoints for the approval of cancer drugs and biologics; 2007. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf.
3. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
4. R. Tuma Progression-free survival remains debatable endpoint in cancer trials J Natl Cancer Inst 101 2009 1439 1441
5. A.M. Stone, W. Bushnell, and J. Denne Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group Eur J Cancer 2011
6. O. Amit, F. Mannino, and A.M. Stone Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis Eur J Cancer 2011
7. L.E. Dodd, E.L. Korn, and B. Freidlin Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense? J Clin Oncol 26 2008 3791 3796
8. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man (CHMP/EWP/205/95 Rev. 3) methodological considerations for using progression-free survival (PFS) as primary endpoint in confirmatory trials for registration; 2008. Available from: http://www.ema.europa.eu/ema/pages/includes/ document/open-document.jsp?webContentId=WC500017749.
9. Z. Zhang, and J. Sun Interval censoring Stat Methods Med Res 19 2010 53 70